Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- Health equity may influence access to diagnosis, specialist referral, and treatment throughout the patient journey.
- Access to specialist expertise and multidisciplinary care may influence diagnosis, treatment initiation, and long-term follow-up.
- Access to imaging, exclusion testing, and follow-up depends on local systems and pathways.
- Barriers to treatment access may contribute to interruptions in therapy and ongoing care.
Why ATTR-CM Equity Problems Start Before Treatment
Health equity may influence timely recognition of ATTR-CM, access to specialist evaluation, and the ability to initiate and maintain disease-modifying therapy. Early recognition, timely referral, and access to appropriate diagnostic evaluation are important components of equitable patient care.
How Specialist Infrastructure Shapes Who Gets Diagnosed
Effective use of diagnostic tools depends on timely access to appropriate expertise and healthcare resources. Access to imaging, appropriate evaluation to exclude light chain (AL) amyloidosis, specialist referral, and longitudinal follow-up may vary across healthcare settings and influence the diagnostic pathway.
Why Policy Barriers Can Look Like Clinical Failure
Challenges related to treatment access may continue after therapy has been initiated. Prior authorization requirements, out-of-pocket costs, and fragmented follow-up may contribute to interruptions in treatment continuity and should be considered when evaluating clinical response. Recognizing these factors as part of comprehensive patient management may help identify barriers to optimal care.
Frequently Asked Questions
Do ATTR-CM equity problems start at the pharmacy counter?
No. Access to timely recognition, appropriate diagnostic evaluation, and specialist referral may influence the patient journey before treatment is initiated.
How does infrastructure affect diagnosis?
Access to imaging, appropriate diagnostic testing, specialist referral, and longitudinal follow-up may vary across healthcare settings and influence the diagnostic process.
Why can access barriers be mistaken for treatment failure?
Access barriers can be mistaken for treatment failure because prior authorization, cost sharing, and fragmented follow-up can interrupt exposure, which may look like poor adherence or weak drug effect when the underlying problem is structural.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Related Access Topics
Next Clinical Decision
See the Evidence
References:
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Baseline Characteristics and Secondary Medication Adherence Among Medicare Patients Diagnosed with ATTR-CM and/or Receiving Tafamidis Prescriptions. Journal of Managed Care & Specialty Pharmacy
- Diagnostic Trends and Geographic Health Care Disparities Among Patients with Transthyretin Amyloid Cardiomyopathy. Journal of the American Heart Association.
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.